Polomar Health Services, Inc. reported a significant decline in financial performance for the second quarter of 2025, with revenues of $5.5 million, a decrease of 62% compared to $14.5 million in the same period of 2024. For the first half of 2025, the company generated $10 million in revenue, down from $28.1 million in the prior year. The gross profit for the second quarter was $3.8 million, compared to $10.3 million in the previous year, reflecting a gross margin contraction. The company recorded a net loss of $605,563 for the quarter, which is a substantial increase from the net loss of $190,742 reported in the second quarter of 2024.
The financial statements indicate that total current assets rose to $93.1 million as of June 30, 2025, up from $76.8 million at the end of 2024, primarily due to an increase in inventory. However, total liabilities decreased to $1.04 million from $1.35 million, largely due to a reduction in related party promissory notes. The stockholders' deficit narrowed slightly to $8.4 million from $8.6 million, despite the increased net loss, indicating ongoing challenges in achieving profitability.
Strategically, Polomar Health Services is focusing on expanding its operational capabilities and product offerings. The company operates Polomar Specialty Pharmacy, which is licensed to dispense compounded medications in 28 states and is actively seeking to expand its reach. The anticipated launch of the SlimRx telehealth platform in Q4 2025 aims to connect patients with healthcare providers for weight loss medications, while PoloMeds is set to fulfill prescriptions for diabetes and dermatological medications. These initiatives are part of a broader strategy to enhance the company's market presence and diversify its revenue streams.
Operationally, Polomar has seen changes in its management structure, with Brett Rosen appointed as President and CFO in early 2024, followed by a series of board appointments and resignations. The company has also entered into various agreements, including a Product Fulfillment and Distribution Agreement with ForHumanity, which allows for exclusive marketing of certain medications. As of June 30, 2025, the company had 27.9 million shares of common stock outstanding, reflecting a slight increase from the previous period.
Looking ahead, Polomar Health Services anticipates that the launch of new products and services, along with geographic expansion, will drive future growth. The company is also exploring potential acquisitions to enhance its business model. However, management cautions that the results for the interim period may not be indicative of future performance, emphasizing the need for continued strategic execution to improve financial outcomes.
About Polomar Health Services, Inc.
Polomar Health Services Inc. operates a licensed specialty pharmacy specializing in sterile and compounded medications across multiple states. It offers prescription fulfillment, including weight loss, diabetes, and dermatological products, often via telehealth partnerships. The company leverages licensed intellectual property and proprietary formulations, focusing on innovative pharmaceutical delivery. Its business model centers on healthcare services, prescription compounding, and online platforms serving diverse patient needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.